Cargando…
Immunotherapy for Prostate Cancer Enters Its Golden Age
In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years, for w...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403579/ https://www.ncbi.nlm.nih.gov/pubmed/22844202 http://dx.doi.org/10.4137/CMO.S7475 |